|
1
|
Nesvick CL, Lafay-Cousin L, Raghunathan A,
Bouffet E, Huang AA and Daniels DJ: Atypical teratoid rhabdoid
tumor: Molecular insights and translation to novel therapeutics. J
Neurooncol. 150:47–56. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sultan I, Qaddoumi I, Rodríguez-Galindo C,
Nassan AA, Ghandour K and Al-Hussaini M: Age, stage, and
radiotherapy, but not the primary tumor site, affects the outcome
of patients with malignant rhabdoid tumors. Pediatr Blood Cancer.
54:35–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zin F, Cotter JA, Haberler C, Dottermusch
M, Neumann J, Schüller U, Schweizer L, Thomas C, Nemes K, Johann
PD, et al: Histopathological patterns in atypical teratoid/rhabdoid
tumors are related to the molecular subgroup. Brain Pathol.
31:e129672021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cacciotti C, Fleming A and Ramaswamy V:
Advances in the molecular classification of pediatric brain tumors:
A guide to the galaxy. J Pathol. 251:249–261. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ginn KF and Gajjar A: Atypical teratoid
rhabdoid tumor: Current therapy and future directions. Front Oncol.
2:1142012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chi SN, Zimmerman MA, Yao X, Cohen KJ,
Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski
C, et al: Intensive multimodality treatment for children with newly
diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol.
27:385–389. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2019.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thompson EM, Bramall A, Herndon JE II,
Taylor MD and Ramaswamy V: The clinical importance of
medulloblastoma extents of resection: A systematic review. J
Neurooncol. 139:523–539. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO Classification of Tumors of the
Central Nervous System: A summary. Neuro Oncol. 23:1231–1251. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chukwueke UN and Wen PY: Use of the
Response Assessment in Neuro-Oncology (RANO) criteria in clinical
trials and clinical practice. CNS Oncol. 8:28–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hilden JM, Meerbaum S, Burger P, Finlay J,
Janss A, Scheithauer BW, Walter AW, Rorke LB and Biegel JA: Central
nervous system atypical teratoid/rhabdoid tumor: Results of therapy
in children enrolled in a registry. J Clin Oncol. 22:2877–2884.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frühwald MC, Hasselblatt M, Nemes K, Bens
S, Steinbügl M, Johann PD, Kerl K, Hauser P, Quiroga E, Solano-Paez
P, et al: Age and DNA methylation subgroup as potential independent
risk factors for treatment stratification in children with atypical
teratoid/rhabdoid tumors. Neuro Oncol. 22:1006–1017. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy AT, Strother DR, Judkins AR, Burger
PC, Pollack IF, Krailo MD, Buxton AB, Williams-Hughes C, Fouladi M,
Mahajan A, et al: Efficacy of high-dose chemotherapy and
three-dimensional conformal radiation for atypical
teratoid/rhabdoid tumor: A Report From the Children's Oncology
Group Trial ACNS0333. J Clin Oncol. 38:1175–1185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Upadhyaya SA, Robinson GW, Onar-Thomas A,
Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK,
Srinivasan A, et al: Relevance of molecular groups in children with
newly diagnosed atypical teratoid rhabdoid tumor: Results from
prospective St. Jude multi-institutional trials. Clin Cancer Res.
27:2879–2889. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schrey D, Carceller Lechón F, Malietzis G,
Moreno L, Dufour C, Chi S, Lafay-Cousin L, Von Hoff K, Athanasiou
T, Marshall LV and Zacharoulis S: Multi-modal therapy in children
and adolescents with newly diagnosed atypical teratoid rhabdoid
tumor: Individual pooled data analysis and review of the
literature. J Neurooncol. 126:81–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lafay-Cousin L, Hawkins C, Carret AS,
Johnston D, Zelcer S, Wilson B, Jabado N, Scheinemann K, Eisenstat
D, Fryer C, et al: Central nervous system atypical teratoid
rhabdoid tumours: The canadian paediatric brain tumour consortium
experience. Eur J Cancer. 48:353–359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pekarek L, Torres-Carranza D,
Fraile-Martinez O, García-Montero C, Pekarek T, Saez MA,
Rueda-Correa F, Pimentel-Martinez C, Guijarro LG, Diaz-Pedrero R,
et al: An Over view of the role of micoRNA on carcinogenesis: A
focus on cell cyle, angionesis and metastasis. Int J Mol Sci.
24:72682023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Torchia J, Golbourn B, Feng S, Ho KC,
Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez
NR, et al: Integrated (epi)-genomic analyses identify
subgroup-specific therapeutic targets in CNS rhabdoid tumors.
Cancer Cell. 30:891–908. 2016. View Article : Google Scholar : PubMed/NCBI
|
